UNSPSC 51111659: Topotecan

This classification denotes a camptothecin analogue, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7M7YKX2N15. European Medicines Agency schedules Topotecan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11191MIG. Topotecan generally arises in the molecular formula C23H23N3O5. The term TOPOTECAN is an International Non-Proprietary Name or INN. TOPOTECAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule topotecan under HS 29399900 and SITC 54149. As of Q4 2014, TOPOTECAN remains the US FDA Preferred Term for this commodity. Topotecan bears US NLM identifiers UMLS ID C0146224 and NCI Concept Code C1413. SMILES: O1CC2C(C(O)(CC)C1=O)CC1N(CC3C1NC1C(C3)C(CN(C)C)C(O)CC1)C2=O.

UNSPSC 51111659 Topotecan is a Commodity code covering the procurement of topotecan, a chemotherapy agent used in cancer treatment. State and local governments purchase this drug primarily through health departments, public health agencies, and state Medicaid programs to support oncology services, cancer treatment protocols, and subsidized care for eligible patients. The drug is typically procured as a finished pharmaceutical product, often through standing agreements or cooperative purchasing vehicles that leverage volume discounts across multiple jurisdictions.

The source provides no recent state or local contract opportunities tagged to this code, making current market activity and issuing-body concentration difficult to characterize. Without posted RFPs, RFQs, IFBs, or ITBs, there is no geographic or temporal signal to guide pursuit strategy at this time.